Spin-labelled photo-cytotoxic diazido platinum(iv) anticancer complex by Venkatesh, V. et al.
University of Huddersfield Repository
Venkatesh, V., Wedge, Christopher J., Romero­Canelón, Isolda, Habtemariam, Abraha and Sadler, 
Peter J.
Spin­labelled photo­cytotoxic diazido platinum(iv) anticancer complex
Original Citation
Venkatesh, V., Wedge, Christopher J., Romero­Canelón, Isolda, Habtemariam, Abraha and Sadler, 
Peter J. (2016) Spin­labelled photo­cytotoxic diazido platinum(iv) anticancer complex. Dalton 
Trans., 45 (33). pp. 13034­13037. ISSN 1477­9226 
This version is available at http://eprints.hud.ac.uk/30046/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not­for­profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
Dalton
Transactions
COMMUNICATION
Cite this: Dalton Trans., 2016, 45,
13034
Received 9th April 2016,
Accepted 6th May 2016
DOI: 10.1039/c6dt01382a
www.rsc.org/dalton
Spin-labelled photo-cytotoxic diazido platinum(IV)
anticancer complex†
V. Venkatesh,a Christopher J. Wedge,b Isolda Romero-Canelón,a
Abraha Habtemariama and Peter J. Sadler*a
We report the synthesis and characterisation of the nitroxide
spin-labelled photoactivatable Pt(IV) prodrug trans,trans,
trans-[Pt(N3)2(OH)(OCOCH2CH2CONH-TEMPO)(Py)2] (Pt-TEMPO,
where TEMPO = 2,2,6,6-tetramethylpiperidine 1-oxyl). Irradiation
with blue visible light gave rise to Pt(II) and azidyl as well as nitroxyl
radicals. Pt-TEMPO exhibited low toxicity in the dark, but on
photoactivation was as active towards human ovarian cancer cells
as the clinical photosensitizer chlorpromazine and much more
active than the anticancer drug cisplatin under the conditions
used.
Platinum-based anticancer drugs are now widely used for the
treatment of various types of cancer.1–3 However, their utility
in the clinic is severely limited by their systemic toxicity, as
well as inherent and acquired drug resistance.4–6 Photo-
activated chemotherapy (PACT) has recently attracted attention
because of its ability to target tumour cells selectively without
causing harm to normal cells thereby minimising side eﬀects.7
The advantages of using metal complexes in PACT stem from
their rich photochemistry.8,9 This can be utilized in the design
of a non-toxic prodrug that can be selectively activated in the
region of a tumour-using light of specific wavelengths, with
longer wavelengths penetrating more deeply into tissues.
Nitroxide spin-labelling can provide a convenient way of
monitoring drug distribution and metabolic pathways using
electron paramagnetic resonance (EPR).10–12 Nitroxyl radicals
often exhibit low toxicity, are membrane-permeable and also
possess antioxidant activity that mimics superoxide dismutase
(SOD).13 The potent anticancer activity of nitroxide radicals,
nitroxyl derivatives and their metal complexes towards a
variety of cancer cell lines has been reported,14–17 and often
involves redox-mediated signalling pathways.18 Nitroxide rad-
icals not only have diagnostic use, but also therapeutic, and
hence are potential ‘theranostics’ as well. We report here what
appears to be (as far as we are aware) the first example of the
photo-release of a nitroxide radical from a metal complex and
its antiproliferative activity towards cancer cells.
We have synthesised the TEMPO-conjugated photo-
activatable Pt(IV) prodrug trans,trans,trans-[Pt(N3)2(OH)
(OCOCH2CH2CONH-TEMPO)(Py)2] (Pt-TEMPO, Fig. 1a) and
studied its photocytotoxicity towards A2780 human ovarian
cancer cells. The synthesis was achieved by reacting trans,
trans,trans-[Pt(N3)2(OH)(succinate)(Py)2] with 4-amino TEMPO
using a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
coupling reaction (ESI, Scheme S1†). The product was purified
by column chromatography and characterized by 1H NMR,
elemental analysis and high resolution mass spectrometry
(HRMS). The presence of the TEMPO radical in the complex
was confirmed by EPR spectroscopy. The EPR spectrum of Pt-
TEMPO (0.5 mM in dichloromethane) recorded at room temp-
erature showed a typical triplet pattern with distinct 14N hyper-
fine splitting (Fig. 1c).
The 1H NMR spectrum of Pt-TEMPO in CDCl3 shows broad-
ened peaks (Fig. S1 ESI†) indicating the presence of the TEMPO
Fig. 1 (a) Molecular structure of Pt-TEMPO complex; (b) calculated and
observed HR-ESI-MS spectra of Pt-TEMPO with isotopic distribution; (c)
EPR spectrum of Pt-TEMPO (0.5 mM) in degassed dichloromethane.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6dt01382a. Data created during this research are openly available from the
University of Warwick Research Archive Portal at http://wrap.warwick.ac.uk/
79055/
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radical attached to the diazido Pt(IV) complex. The peaks in the
aromatic region of the spectrum indicate the presence of pyri-
dine ligands and the signals at (2.3–2.8 ppm) correspond to the
methylene protons in the succinate chain. The signals at
(0.9–1.3 ppm) confirmed the successful conjugation of TEMPO
unit in Pt-TEMPO. The observed HRMS is in good agreement
with the spectrum calculated for [M + Na]+, Fig. 1b.
Pt-TEMPO was irradiated with 420 nm light in aqueous
solution. The progress of the photoreaction was monitored at
diﬀerent time intervals by UV-Vis spectroscopy and the
decomposition products were subsequently analysed by
ESI-MS. The change in ligand-to-metal charge-transfer (LMCT)
band for Pt-TEMPO was monitored after every 30 min of photo-
activation at 420 nm up to 2 h Fig. 2c. The reduction in LMCT
band indicates that there is loss of an azido ligand and/or elec-
tron transfer from azido ligands to Pt(IV) resulting in the for-
mation of azidyl radicals and Pt(IV/II) species. ESI-MS shows
the formation of a mixture of products 1–4 in solution after
photoactivation Fig. 2a (ESI, Fig. S3†). When the photoactiva-
tion was carried out using green light (517 nm), the reduction
in intensity of the LMCT band was very slow (ESI, Fig. S5†) due
to the weaker absorbance of Pt-TEMPO at 517 nm.
To capture the reactive azidyl radicals, spin-trapping experi-
ments were performed. An aqueous solution containing 1 mM
of Pt-TEMPO and 25 mM 5,5-dimethyl-1-pyrroline-N-oxide
(DMPO), giving a 12.5 fold molar excess of spin-trap over
azide, was used for the experiment. The EPR spectrum was
recorded in the dark and during irradiation with a 405 nm
laser (42 mW). In the absence of irradiation the EPR spectrum
showed a triplet signal characteristic of the 2,2,6,6-tetramethyl-
1-piperidinyloxy (TEMPO) radical present in Pt-TEMPO
(Fig. S4†). Upon irradiation with the blue laser the azidyl
Fig. 2 (a) Photoreaction pathways for Pt-TEMPO (0.1 mM in H2O) on irradiation with blue visible light showing formation of products 1–4; (b) EPR
spectrum of Pt-TEMPO with DMPO in the dark as well as after irradiation with λirr = 405 nm laser (each consecutive scan took 21 s to record); (c)
UV-Vis spectrum of Pt-TEMPO after every 30 min of irradiation (λirr = 420 nm).
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adduct of DMPO was detected. This gave a 1 : 2 : 2 : 1 quartet of
triplets signal along with the triplet signal of the stable
TEMPO radical. During irradiation, spectra were recorded
continuously with each successive field-sweep taking 21 s
(Fig. 2b).
Due to the overlap of peaks for Pt-TEMPO and the
DMPO-N3 adduct, and the significant intensity diﬀerence
between them, it is diﬃcult to obtain accurate spin Hamil-
tonian parameters of the weaker component through a multi-
component fit. For simulations of the DMPO azidyl adduct the
hyperfine couplings were therefore fixed to literature values
(aNNO = 1.45 mT, a
H
β = 1.49 mT, a
N
α = 0.316 mT).
19 By subtracting
the experimental data recorded before illumination from those
recorded after illumination, the Pt-TEMPO signal intensity
was significantly reduced allowing the twelve-line azidyl spin-
adduct signal to be observed clearly (Fig. 3a). As aNNO ≈ aHβ the
usual DMPO doublet of triplets overlaps to form a 1 : 2 : 2 : 1
quartet, with each line further split into a triplet by the small
coupling to the azidyl nitrogen. This spectral assignment has
been confirmed previously in photoactivation studies of a
closely related Pt-azidyl anti-cancer compound by use of 15N
labelled azide,19 hence it was not considered necessary to
perform isotopic substitution experiments.
Once individual spectral simulations for Pt-TEMPO and the
azidyl radical adduct had been completed using EasySpin20 it
was possible to reproduce the overlapping experimental
spectra as linear combinations of the two (Fig. 3b). The scaling
parameter between simulated and experimental spectra was
determined from a least-squares fit of the simulated
Pt-TEMPO spectra to the experimental spectra prior to illumi-
nation. Treating this value as a constant and using the known
initial Pt-TEMPO concentration of 1 mM as a reference, it was
possible to determine the azidyl adduct concentration from
the weighting factor of the combined fit. Running the spectro-
meter in incremental scan mode, a series of field-swept
spectra was recorded consecutively, which by individual fitting
with the simulated spectra allowed measurement of the azidyl-
adduct concentration as a function of time since illumination
began (Fig. 3c).
The photocytotoxicity of Pt-TEMPO was determined by
using the sulforhodamine B (SRB) colorimetric assay which
quantifies protein content of treated samples against
untreated controls. A2780 human ovarian carcinoma cells were
treated with Pt-TEMPO for 1 h in the dark and also treated
with Pt-TEMPO followed by irradiation with blue light (50 mW
at 465 nm) for 1 h. The complex was not toxic in the dark but
potently cytotoxic when irradiated in the cells with blue visible
light, giving a phototoxicity index (PI) of >8. A2780 cells are
>14× more sensitive to Pt-TEMPO than to cisplatin when
treated under the same conditions. The activity of cisplatin
was not aﬀected by the irradiation. The photocytotoxicity of
Pt-TEMPO is similar to that21 of the parent trans-dihydroxido
Fig. 3 (a) Overlap of experimental and simulated DMPO-N3 adduct spectra. The experimental trace shows the subtraction of spectra recorded
immediately before and after switch on of the light source. Stars indicate the location of the three main lines in the TEMPO spectrum which are not
fully subtracted; (b) comparison between simulated and experimental EPR spectra of Pt-TEMPO and DMPO-N3; (c) azide spin-adduct concentration
as a function of illumination time (42 mW at 405 nm) determined by least-squares ﬁtting of the sum of simulated Pt-TEMPO and DMPO-N3 spectra
to the experimental EPR traces.
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complex [Pt(N3)2(OH)2(Py)2] which shows that replacement of
one axial hydroxide ligand by a TEMPO-conjugated succinate
ligand does not diminish the activity. Interestingly, the activity
of the new complex Pt-TEMPO is as high as the organic photo-
sensitizer chlorpromazine (CPZ) (Table 1).
In summary, a diazido Pt(IV) pro-drug trans,trans,trans-
[Pt(N3)2(OH)(OCOCH2CH2CONH-TEMPO)(Py)2] (Pt-TEMPO)
spin-labelled with a nitroxyl radical has been synthesised. It is
non-toxic in the dark but potently cytotoxic towards cancer
cells when irradiated with visible light. The photocytotoxicity
is as high as the clinical photosensitizer chlorpromazine and
much more cytotoxic than anticancer drug cisplatin under the
same conditions. EPR experiments showed that photoactiva-
tion of Pt-TEMPO with blue light leads to the formation of
azidyl and TEMPO radicals in solution. The reactive azidyl rad-
icals were captured by the spin trap DMPO. The anticancer
activity of Pt-TEMPO may be the result of attack on DNA by the
Pt(II) photoproducts as well as the activity of the reactive azidyl
and appended TEMPO radicals. The complex should be suit-
able for the treatment of surface cancers such as bladder and
oesophagus, and if deeper light penetration is required then
either two-photon activation or coupling to an upconversion
nanoparticle system may be possible.22,23
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